CervoMed (CRVO) grants director David Quigley options on 8,150 shares

Rhea-AI Filing Summary

CervoMed Inc. director David Quigley received a stock option grant as part of his compensation for joining the board. On June 8, 2026, he was awarded options to buy 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share, expiring on June 8, 2036.

The grant was made under the company’s 2025 Equity Incentive Plan and its non-employee director compensation policy. The underlying shares vest in substantially equal 1/12 monthly installments over one year, starting June 30, 2026, subject to his continued board service.

Insights

Equity compensation analyst

Routine director option grant with time-based vesting at fixed strike.

The filing shows CervoMed granted director David Quigley options on 8,150 shares of common stock at an exercise price of $2.91 per share, expiring on June 8, 2036. This is a compensation-related award, not an open-market transaction.

The options were granted under the 2025 Equity Incentive Plan and follow the non-employee director compensation policy, indicating a standardized program. Vesting is monthly over one year starting June 30, 2026, conditioned on continued service, aligning director incentives with ongoing board participation.

Because this is a routine grant with no immediate cash outlay and no sale of shares, it usually carries limited signaling value about management’s view of the stock. Future company filings may provide additional context on overall equity awards and potential dilution levels.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Quigley David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,150	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 8,150 shares (Direct)

Footnotes (1)

1. F1. On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Option shares granted: 8,150 shares Exercise price: $2.91 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option shares granted 8,150 shares Stock option grant to director David Quigley on June 8, 2026

Exercise price $2.91 per share Strike price for Quigley’s stock options

Expiration date June 8, 2036 Option term under the 2025 Equity Incentive Plan

Vesting schedule 1/12 monthly over one year Vesting begins June 30, 2026, subject to continued service

Shares underlying options after grant 8,150 shares Total derivative holdings reported following the transaction

Key Terms

Stock Option (Right to Buy), 2025 Equity Incentive Plan, non-employee director compensation policy, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

2025 Equity Incentive Plan financial

"granted an option ... under the Issuer's 2025 Equity Incentive Plan"

non-employee director compensation policy financial

"in accordance with the terms of the Issuer's non-employee director compensation policy"

vesting financial

"underlying the award will vest on a monthly basis over a one-year period"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/10/2026 - 07:44 PM Accepted by SEC EDGAR 06/10/2026 - 07:44 PM Learn about SEC filing dates

FAQ

What did CervoMed (CRVO) director David Quigley receive in this Form 4 filing?

David Quigley received a stock option grant for 8,150 CervoMed shares. The options were awarded as part of his election to the board and issued under the 2025 Equity Incentive Plan according to the non-employee director compensation policy.

What is the exercise price and term of David Quigley’s CervoMed (CRVO) stock options?

The options have an exercise price of $2.91 per share and expire on June 8, 2036. This means Quigley can buy up to 8,150 shares at $2.91 any time before that expiration date, once the options have vested.

How do David Quigley’s CervoMed (CRVO) options vest over time?

The 8,150-share option award vests monthly over one year in substantially equal 1/12 increments. Vesting begins on June 30, 2026 and continues on the last day of each month, subject to Quigley’s continued service on the board.

Is David Quigley’s CervoMed (CRVO) Form 4 transaction a stock purchase or sale?

The Form 4 reports an option grant, not a market purchase or sale. It is coded as a grant or award acquisition, giving Quigley the right to buy shares in the future, rather than reflecting an immediate buy or sell transaction.

Why did CervoMed (CRVO) grant stock options to David Quigley?

The options were granted in connection with Quigley’s election to CervoMed’s board at the 2026 Annual Meeting of Stockholders. They were issued under the 2025 Equity Incentive Plan according to the company’s non-employee director compensation policy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quigley David

(Last) (First) (Middle)

C/O CERVOMED INC

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.91	06/08/2026		A		8,150		(1)	06/08/2036	Common Stock	8,150	$0	8,150	D

Explanation of Responses:

1. On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)